Hemotology Flashcards
Factor VIII and Factor IX
Classification
Antihemophilic Factor
Factor VIII and Factor IX
Indication
Factor VIII = Hemophilia A
Factor IX = Hemophilia B
-replaces missing coagulation factor, which reduces bleeding and joint damage
Factor VIII and Factor IX
MOA
Clotting factor replacements and cofactors for factor Xa
Factor VIII and Factor IX
Prototypes
plasma derived factor VIII concentrate (Hemofil-M)
recombinant factor VIII (Advate)
plasma-derived factor IX concentrate (Alpha-Nine S-D)
recombinant factor IX concentrate (BeneFix)
Factor VIII and Factor IX
Adverse effects
Hypersensitivity
Prion diseases
Factor VIII and Factor IX
Nursing interventions
Monitor for allergies - rash, itching, anaphylaxis
-diphenydramine, epinephrine
Factor VIII and Factor IX
Administration
Reconstitute
IV bolus over 5-10 min
Treatment for bleeding or prophylaxis (1-3X per week)
Desmopressin
Class
Antidiuretic
Desmopressin
Indication
Short term control of bleeding for Hemophilia A (injury or prep for surgery)
Desmopressin
Prototype
desmopressin (DDAVP, Stimate)
Desmopressin
MOA
Stimulates release of stored factor VIII (must be able to create factor VIII and does not work for Hemophilia B)
Desmopressin
Adverse effects
Dilutional hyponatremia
Fluid retention
Seizures
Drowsiness
Headache
Nausea
GI discomfort
Desmopressin
Interventions
Monitor serum sodium and I&Os
Restrict fluids and salt with overload, possible diuretic therapy
Monitor for diabetes insipidus
Desmopressin
Admin
IV or intranasal
IV: Dilute in 0.9% NaCl and administer over 15-30 min
Intranasal: Stimate, be careful to spray the exact number of times for the dose otherwise overdose can occur
Desmopressin
Teaching
Weigh daily and report sudden changes
Report uncontrolled bleeding, dyspnea, headache
Avoid alcohol
Desmopressin
Contraindications
Renal failure
Nephrogenic diabetes insipidus
Type IIB von Willebrand’s disease
Heart failure (precaution)
Factor Xa/Thrombin Inhibitors
Prototype
heparin - thrombin inhibitor
Enoxaparin (Levenox) - factor Xa in hibitor
Factor Xa/Thrombin Inhibitors
Classification
Anticoagulants
Factor Xa/Thrombin Inhibitors
Indication
Prevent blood clots from forming or worsening:
-CVA treatment
-DVT and pulmonary emboli prevention
-Surgery, hemodialysis, blood transfusions
-DIC treatment
-post MI
Factor Xa/Thrombin Inhibitors
MOA
Binds with antithrombin and inactivates factor Xa and thrombin
Prevents fibrin development
Factor Xa/Thrombin Inhibitors
Adverse effects
Bleeding/Hemorrhage
Thrombocytopenia due to autoimmune reaction to protein in heparin
Hypersensitivity
Factor Xa/Thrombin Inhibitors
Interventions
Monitor for hypotension/tachy indicating bleeding
Monitor activated partial thromboplastin time (aPTT) - should be no longer than twice the baseline
Administer protamine for long aPTT or bleeding
Factor Xa/Thrombin Inhibitors
Admin
Subq or IV
Get baseline aPTT, CBC, platelet, and hct
Monitor aPTT for heparin q 4-6 h
(Enoxaparin dose is based on weight and does not need aPTT monitoring)
Factor Xa/Thrombin Inhibitors
Instructions
Report bleeding, bruising, petechiae, black stools, hematomas
Report calf pain, swelling, redness or warmth, dyspnea
Do not take NSAIDS
Use soft toothbrush
Avoid razors
Factor Xa/Thrombin Inhibitors
Contraindications
Thrombocytopenia
Uncontrollable bleeding
Lumbar puncture, epidural, regional anesthesia, or any surgery involving brain, spinal cord, or eyes
Pregnancy (miscarriage risk)
Vitamin K Antagonists
Prototype
Warfarin (Coumadin)
Vitamin K Antagonists
Indication
Prevents DVT with pulmonary emboli, CVAs secondary to a fib, thromboemboli with prosthetic valves, and reoccurring MI
Treats TIAs
Vitamin K Antagonists
Class
Anticoagulant
Vitamin K Antagonists
MOA
Block action of vitamin K, which is needed in synthesis of clotting factors VIII, IX, and X and prothrombin
Vitamin K Antagonists
Adverse effects
Bleeding
Vitamin K Antagonists
Interventions
Monitor for signs of bleeding
Administer vitamin K slowly via IV if hemorrhage occurs
Administer blood products if vitamin K doesn’t work
Vitamin K Antagonists
Admin
PO
Monitor PT/INR daily until correct dosage then every 2-4 weeks (INR result needed to determine daily dose)
Takes 8-12 hours for onset of anticoagulation
Vitamin K Antagonists
Contraindications
Pregnancy
Vitamin K deficiency
Thrombocytopenia
Liver disease
Alcoholism
Uncontrolled bleeding
Regional anesthesia, lumbar puncture, or surgery involving CNS and eyes
Thrombolytics
Prototype
alteplase (Activase)
streptokinase (Streptase)
reteplase (Retevase)
tenecteplase (TNKase)
Thrombolytics
Indication
Breaks down blood clots that have already formed
-treats PE, MI, CVA, DVT
-re-establish patency of occluded IV
Thrombolytics
MOA
Selectively convert plasminogen into plasmin, which is an enzyme that breaks down fibrin (breaks down clot) and clotting factors (prevents new clots from forming)
Thrombolytics
Adverse Effects
Bleeding
Thrombolytics
Interventions
Monitor intracranial bleed: consciousness, orientation, headache,
Monitor GI bleed: abdominal pain, dark stool, VS
Limit venipuncture/injections
Apply pressure to puncture sites
Administer aminocaproic acid (Amicar) for bleeding to facilitate clotting
Thrombolytics
Admin
IV post MI, CVA etc.
Obtain INR, PT, aPTT, hct, etc.
Ensure patent secondary IV for emergency
Monitor neuro status q 30 min for 8 hours after admin
Thrombolytics
Contraindications
Prior intracranial hemorrhage
Hemorrhagic CVA
Aortic dissection
Aneurysm
Acute pericarditis
Brain tumor
Recent head trauma
Erythropoietic Growth Factors
Prototype
epoetin alfa (Epogen, Procrit)
darbepoetin alfa (Aranesp): long-acting
Erythropoietic Growth Factors
Indication
Increases erythrocyte production in renal failure, preop anemia, chemotherapy, or taking Retrovir for HIV
Erythropoietic Growth Factors
Class
Erythropoiesis stimulating agents
Erythropoietic Growth Factors
Adverse effects
HTN due to increased hct
CVA, MI, cardiac arrest due to increased hgb
Seizures
Progression of cancer
Erythropoietic Growth Factors
MOA
mimics natural erythropoieten secreted by the adrenal glands by stimulating RBC production in bone marrow
Erythropoietic Growth Factors
Admin
IV or subq 3x per week
Do not shake or mix
Monitor hgb 2x per week until optimal dose obtained and report hgb over 12
Monitor iron level
Erythropoietic Growth Factors
Contraindications
Uncontrolled HTN
Cancer w/o chemo or radiation
Hypersensitivity
Iron deficiency anemia (not effective)
Leukopoietic Growth Factor
Prototype
fligrastim (Neupogen)
Leukopoietic Growth Factor
Class
Colony-Stimulating Factors
Leukopoietic Growth Factor
Indication
Increase WBCs - used to prevent infection with bone marrow transplant, myelosuppresive chemo, or chronic neutropenia
Leukopoietic Growth Factor
MOA
Stimulates bone marrow to increase stem cell production of leukocyte precursors
Leukopoietic Growth Factor
Adverse effects
Leukocytosis
Bone pain
Fever
Splenomegaly (gets clogged with cells with long-term use)
Hypersensitivity and acute respiratory distress
Leukopoietic Growth Factor
Admin
Baseline CBC
Monitor CBC 2x per week
IV or subq
Avoid administering within 24 hours of chemotherapy
Leukopoietic Growth Factor
Interventions
Monitor CBC - report to provider if WBC is over 10,000
Administer acetaminophen for mild bone pain and fever
Leukopoietic Growth Factor
Contraindications
Sensitivity to E. coli derived proteins
ARDS
Currently undergoing chemo or radiation
Thrombopoietic Growth Factor
Prototype
oprelvelkin (Interleukin-11 and Neumega)
Thrombopoietic Growth Factor
Indication
Treats thrombocytopenia from myelosuppresive chemo for non-myeloid cancers (decreases need for platelet transfusions)
Thrombopoietic Growth Factor
MOA
Stimulates synthesis of megakaryocytes (precursor of platelets) in bone marrow
Thrombopoietic Growth Factor
Adverse effects
Fluid retention and dilutional anemia
Dysrhythmias secondary to fluid retention
Hypersensitivity
Conjunctival infection is common
Thrombopoietic Growth Factor
Admin
Baseline CBC, electrolyte panel
Subq QD 4-6 hours after chemo and do not administer more than 21 days
Thrombopoietic Growth Factor
Interventions
Monitor for dysrhythmias
Monitor fluid intake and output and signs of retention
Monitor for allergic reaction
Thrombopoietic Growth Factor
Contraindication
Use with caution with HF or pleural effusion
Use with caution with myeloid cancer